×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.96 (+1.71%)
AAPL   141.56 (+1.89%)
MSFT   262.85 (+1.26%)
META   168.19 (+5.10%)
GOOGL   2,265.26 (+4.16%)
AMZN   113.50 (+3.60%)
TSLA   699.20 (+2.55%)
NVDA   149.64 (+3.04%)
NIO   22.18 (+3.84%)
BABA   120.13 (+3.56%)
AMD   75.20 (+2.08%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.17 (-0.66%)
GE   62.03 (-2.38%)
F   11.20 (-1.06%)
DIS   97.18 (+1.08%)
AMC   12.78 (-5.54%)
PFE   51.64 (-1.28%)
PYPL   74.40 (+4.20%)
NFLX   185.88 (+3.30%)
OTCMKTS:LZAGY

Lonza Group Stock Forecast, Price & News

$54.98
+0.32 (+0.59%)
(As of 07/5/2022 03:58 PM ET)
Add
Compare
Today's Range
$54.23
▼
$55.68
50-Day Range
$50.05
▼
$60.24
52-Week Range
$49.70
▼
$86.31
Volume
484,084 shs
Average Volume
104,701 shs
Market Capitalization
$40.94 billion
P/E Ratio
N/A
Dividend Yield
0.16%
Price Target
N/A

Lonza Group MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.66mentions of Lonza Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
21.47%
From $1.63 to $1.98 Per Share

Overall MarketRank™

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.87 out of 5 stars

See Top Rated MarketRank™ Stocks Here
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart

Receive LZAGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lonza Group and its competitors with MarketBeat's FREE daily newsletter.

Lonza Group logo

About Lonza Group (OTCMKTS:LZAGY) Stock

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.

LZAGY Stock News Headlines

June 29, 2022 | americanbankingnews.com
Lonza Group AG (OTCMKTS:LZAGY) Short Interest Update
June 19, 2022 | americanbankingnews.com
Lonza Group AG (OTCMKTS:LZAGY) Receives $842.50 Consensus Target Price from Analysts
June 18, 2022 | seekingalpha.com
Lonza: One Stop Shop For Global Drug Manufacturing, At A Price
March 10, 2022 | seekingalpha.com
Lonza finishes laboratory expansion at API manufacturing facility in China
January 29, 2022 | seekingalpha.com
Lonza Group AG GAAP EPS of CHF39.52, revenue of CHF5.4B
January 27, 2022 | finance.yahoo.com
HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate
January 26, 2022 | ca.finance.yahoo.com
Lonza's full-year core EBITDA up 20.7% on vaccine demand
January 19, 2022 | nasdaq.com
Lonza Group AG ADR (LZAGY)
November 13, 2021 | finance.yahoo.com
Should You Have Lonza Stock on Your Watchlist?
July 27, 2021 | finance.yahoo.com
Moderna Slips As Issues At Partners Delay Overseas Release Of Shots
July 27, 2021 | finance.yahoo.com
UPDATE 2-Supply issues to delay Moderna COVID-19 vaccine shipments, S.Korea says
July 23, 2021 | finance.yahoo.com
RPT-UPDATE 2-Vaccine business helps Lonza lifts 2021 sales outlook
July 23, 2021 | finance.yahoo.com
Vaccine business helps Lonza lifts 2021 sales outlook
June 21, 2021 | finance.yahoo.com
Lonza Group Ag (LZAGY) Upgraded to Buy: What Does It Mean for the Stock?
May 17, 2021 | finance.yahoo.com
Gracell Biotechnologies Reports First Quarter 2021 Unaudited Financial Results and Provides Corporate Update
April 29, 2021 | finance.yahoo.com
Lonza says 3 Moderna vaccine ingredient lines to be at capacity by end-June
April 29, 2021 | finance.yahoo.com
UPDATE 2-Switzerland's Lonza to boost production for Moderna COVID-19 vaccine
April 27, 2021 | finance.yahoo.com
REFILE-Nestle staff sought to help Lonza production for Moderna vaccine -Swiss TV
April 19, 2021 | finance.yahoo.com
Herens Midco S.a.r.l. -- Moody's assigns B3 Corporate Family Rating to Herens Midco S.a.r.l.; outlook positive
April 19, 2021 | finance.yahoo.com
Herens HoldCo S.a.r.l. -- Moody's assigns B3 Corporate Family Rating to Herens Midco S.a.r.l.; outlook positive
April 18, 2021 | uk.finance.yahoo.com
Lonza Group Stock Shows Every Sign Of Being Significantly Overvalued
April 14, 2021 | finance.yahoo.com
aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810
April 12, 2021 | finance.yahoo.com
UPDATE 1-Spain's Rovi to make ingredients for Moderna's COVID-19 vaccine
March 15, 2021 | finance.yahoo.com
UPDATE 1-Lonza gets licence to make ingredients for Moderna vaccine
February 19, 2021 | finance.yahoo.com
Bowtie German Bidco GmbH -- Moody's assigns B3 CFR to NextPharma, outlook stable
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Tobacco products
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:LZAGY
CUSIP
N/A
CIK
1446711
Web
www.lonza.com
Phone
(161) 316-8111
Fax
41-61-316-9111
Employees
16,540
Year Founded
1897

Company Calendar

Ex-Dividend for 5/26 Dividend
5/09/2022
Dividend Payable
5/26/2022
Today
7/05/2022
Fiscal Year End
12/31/2022

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
33.73
P/E Growth
1.37
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
2.51
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$5.92 billion
Price / Sales
6.92
Cash Flow
$1.80 per share
Price / Cash Flow
30.57
Book Value
$14.43 per share
Price / Book
3.81

Miscellaneous

Outstanding Shares
744,690,000
Free Float
N/A
Market Cap
$40.94 billion
Optionable
Not Optionable
Beta
0.93

Social Links















Lonza Group Frequently Asked Questions

Should I buy or sell Lonza Group stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lonza Group in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lonza Group stock.
View analyst ratings for Lonza Group or view top-rated stocks.

How has Lonza Group's stock performed in 2022?

Lonza Group's stock was trading at $83.50 at the start of the year. Since then, LZAGY shares have decreased by 34.2% and is now trading at $54.98.
View the best growth stocks for 2022 here.

Are investors shorting Lonza Group?

Lonza Group saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 33,800 shares, an increase of 2,716.7% from the May 31st total of 1,200 shares. Based on an average trading volume of 247,400 shares, the short-interest ratio is currently 0.1 days.
View Lonza Group's Short Interest.

How often does Lonza Group pay dividends? What is the dividend yield for Lonza Group?

Lonza Group announced a dividend on Wednesday, May 4th. Shareholders of record on Tuesday, May 10th will be paid a dividend of $0.0895 per share on Thursday, May 26th. This represents a yield of 0.39%. The ex-dividend date of this dividend is Monday, May 9th.
View Lonza Group's dividend history.

Is Lonza Group a good dividend stock?

Lonza Group(OTCMKTS:LZAGY) pays an annual dividend of $0.09 per share and currently has a dividend yield of 0.16%.
View Lonza Group's dividend history.

Who are Lonza Group's key executives?

Lonza Group's management team includes the following people:
  • Dr. Pierre-Alain Ruffieux Ph.D., Chief Exec. Officer (Age 53, Pay $2.7M)
  • Mr. Philippe Deecke, Chief Financial Officer (Age 50)
  • Mr. Stefan Stoffel, Head of Group Operations (Age 56)
  • Mr. Dirk Oehlers, VP of Investor Relations
  • Mr. Andreas Bohrer, Group Gen. Counsel & Company Sec.
  • Ms. Victoria Morgan, Head of External Communications
  • Ms. Jennifer Clancy, Sr. Director of Global Marketing
  • Ms. Caroline Barth, Chief HR Officer (Age 50)
  • Ms. Constance Ward, Head of External Communications
  • Dr. Sanna Fowler, Head of External Communications

Who are some of Lonza Group's key competitors?

Some companies that are related to Lonza Group include Imperial Brands (IMBBY), Turning Point Brands (TPB), Healthier Choices Management (HCMC), Gilla (GLLA) and Pharming Group (PHGUF).
View all of LZAGY's competitors.

What is Lonza Group's stock symbol?

Lonza Group trades on the OTCMKTS under the ticker symbol "LZAGY."

How do I buy shares of Lonza Group?

Shares of LZAGY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lonza Group's stock price today?

One share of LZAGY stock can currently be purchased for approximately $54.98.

How much money does Lonza Group make?

Lonza Group (OTCMKTS:LZAGY) has a market capitalization of $40.94 billion and generates $5.92 billion in revenue each year.

How many employees does Lonza Group have?

Lonza Group employs 16,540 workers across the globe.

Does Lonza Group have any subsidiaries?

The following companies are subsidiares of Lonza Group: Arch Acquisition LLC, Arch Chemicals Canada Inc., Arch Chemicals Inc., Arch Chemicals Limited, Arch Chemicals Receivables LLC, Arch Chemicals SAS, Arch Personal Care Products L.P., Arch Protection Chemicals Private Limited, Arch Quimica Argentina S.R.L., Arch Quimica Brasil Ltda., Arch Timber Protection B.V., Arch Treatment Technologies Inc., Arch UK Biocides Limited, Arch Water Products France S.A.S., Arch Water Products South Africa (Pty) Ltd, Arch Wood Protection (Aust) Pty Ltd, Arch Wood Protection (M) Sdn. Bhd., Arch Wood Protection (NZ) Limited, Arch Wood Protection (SA) Pty Ltd, Arch Wood Protection Canada Corp., Arch Wood Protection Inc, Bend Research Inc., BioAtrium AG, CH Capsules Malaysia SDN BHD, Capsugel, Capsugel (Thailand) Co. Ltd, Capsugel Australia Pty Ltd, Capsugel Belgium NV, Capsugel Brasil Importação e Distribuição de Insumos Farmacêuticos e Alimentos Ltda., Capsugel Canada Corp., Capsugel Distribucion S. de R.L. de C.V., Capsugel FinanceCo II S.à r.l., Capsugel FinanceCo S.C.A., Capsugel FinanceCo S.à r.l, Capsugel France Holdings SAS, Capsugel France SAS, Capsugel Funding LLC, Capsugel Germany GmbH, Capsugel Healthcare Private Limited, Capsugel Holdings (Hong Kong) Limited, Capsugel Holdings S.à r.l., Capsugel Holdings US Inc., Capsugel Hungary Kft, Capsugel Inc., Capsugel Italy S.R.L., Capsugel Japan Inc., Capsugel Manufacturing Inc., Capsugel Middle East Sàrl, Capsugel New Zealand Limited, Capsugel Pharmaceutical and Health Products Marketing Ltd, Capsugel Philippines Inc., Capsugel Ploermel SAS, Capsugel S.à r.l., Capsugel Spain S.L., Capsugel US LLC, Capsugel de México S. de R.L. de C.V., Diacon Technologies, Diacon Technologies Limited, Hickson Ltd, InterHealth Nutraceuticals, InterHealth Nutraceuticals Incorporated, LLC Capsugel, Lonza (China) Investments Co. Ltd., Lonza AG, Lonza America Inc., Lonza Argentina S.A, Lonza Biologics Inc., Lonza Biologics Porriño S.L., Lonza Biologics Tuas Pte. Ltd, Lonza Biologics plc, Lonza Bioscience SARL, Lonza Bioscience Singapore Pte Ltd, Lonza Biotec s.r.o., Lonza Cologne GmbH, Lonza Colombia S.A.S, Lonza Copenhagen ApS, Lonza Costa Rica S.A., Lonza Geleen B.V., Lonza Guangzhou Ltd, Lonza Guangzhou Nansha Ltd, Lonza Houston Inc., Lonza Inc., Lonza India Private Limited, Lonza Israel Ltd, Lonza Japan Ltd, Lonza Luxembourg S.à r.l., Lonza Microbial Control Asia Pacific Pte Ltd, Lonza Milano S.r.l., Lonza NZ Limited, Lonza Nanjing Ltd, Lonza Netherlands B.V, Lonza Rockland Inc., Lonza Sales AG, Lonza Shanghai International Trading Ltd, Lonza Suzhou Ltd, Lonza Swiss Finanz AG, Lonza Swiss Licences AG, Lonza Verviers SPRL, Lonza Walkersville Inc., Lonza do Brasil Especialidades Quimicas Ltda., MW Encap (Holdings) Limited, MW Encap Limited, Micro-Macinazione, Micro-Macinazione SA, Octane Biotech, Octane Biotech Inc, P.T. Capsugel Indonesia, PharmaCell, Powdersize LLC, Suzhou Capsugel Limited (JV), Triangle Research Labs, Xcelience Clinical Services Ltd, Xcelience LLC, and Zelam Holdings.
Read More

When was Lonza Group founded?

Lonza Group was founded in 1897.

How can I contact Lonza Group?

Lonza Group's mailing address is Muenchensteinerstrasse 38, Basel V8, 4002. The official website for Lonza Group is www.lonza.com. The company can be reached via phone at (161) 316-8111, via email at investor.relations@lonza.com, or via fax at 41-61-316-9111.

This page (OTCMKTS:LZAGY) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.